

12-16-03

Docket No: AM101017

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of:

Eric L. Lien, Charles F. Kuhlman

Application No.:

10/663,923

Group Art No.:

Not Yet Assigned

Filed:

September 16, 2003 Examiner:

Not Yet Assigned

For:

INFANT FORMULA CONTAINING PARTIALLY HYDROLYZED

ISOLATED SOY PROTEIN WITH A REDUCED PHYTATE

CONTENT

Confirmation No.:

Not Yet Assigned

Customer Number:

25291

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EU947816309US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

<u> XVecember 15, 2003</u> Date *Dubrnia d*.
Bubinea D.Owens

Docket No: AM101017 Patent

2.	Identi	ificatio	on of Time of Filing			
	This I	Inform	ation Disclosure Statement			
	a.	\boxtimes	is filed within three months of the filing	g date of the appli	cation.	
	b.		is filed before the mailing date of a first	st Office Action or	ı the merit	s.
	C.		is filed before the mailing date of a first request for continued examination un-	st Office Action af	ter the filir	
	d.		is filed after the period specified in 2(a mailing date of a final action under 37 a certification under 37 CFR 1.97(e) g	a), 2(b) or 2(c) abo CFR 1.311. This or the fee set forth	ove, but be s statemer in 37 CFI	nt includes R 1.17(p).
	e.		is filed after the mailing date of a final before payment of the issue fee. This under 37 CFR 1.97(e), <u>and</u> (ii) the fee	s statement includ	les (i) a ce	ertification
3.			fication under 37 CFR 1.97(e) and 1.70 undersigned attorney certifies	04(d)		
	a.		that each item of information contained Statement was first cited in any common a counterpart foreign application not filing of the statement, or	nunication from a	foreign pa	itent office
	b.		that no item of information contained Statement was cited in a communical counterpart foreign application or, to the certification after making reasonal individual designated in 37 CFR 1.56 the filing of the statement.	tion from a foreign the knowledge of t ble inquiry, was ki	n patent of the persor nown to a	fice in a n signing ny
	C.		The undersigned attorney certifies the in the Information Disclosure Statemer a foreign application patent office in a was not received by any individual dethan thirty (30) days prior to the filing	ent was cited in a n counterpart foreig esignated in 37 CF	communio gn applica	cation from ation and
		A leg attac applie natio	y Cited Information ible copy of the patents, publications of hed form PTO 1449 is enclosed, excel cation is enclosed, and if this patent ap nal stage after June 30, 2003, no copy cation publication is enclosed.	pt that no copy of oplication was filed	a pending d or enter	U.S. ed the
		No conformate to the under	iously Cited Information opy of the patents, publications or othe PTO-1449 is enclosed because it has e Office in a prior application which is r or 35 USC 120. application is Application Number	been previously of	cited by or	submitted
			application to Application Hambon	, 11100 011	٥.	. •••

Docket No: AM101017 Patent

a. b.	Concise Explanation Documents cited above which are not in the English Language have been explained in the specification. have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.
Form	PTO-1449 is enclosed in duplicate.
	Fees Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00
Char	ood of Payment of Fees: ge Deposit Account No. 01-1425 in the amount of \$0.00 plicate of this statement is enclosed.
	uctions as to Overpayment/Underpayment: it any overpayment and charge any underpayment to Deposit Account No. 425.
	Michael R. Nagy Attorney for Applicants Reg. No. 33,432

Wyeth Patent Law Department Five Giralda Farms Madison, NJ 07940 Tel. No. (484) 865-8616

				Con	nplete if Known	
Gubalitute for form	1449/PTO			Application Number	10/663,923	
5/	INFORMATION DISCLO	SURE		Filing Date	September 16, 2003	
DEC 1 5 2003	STATEMENT BY APPL			First Named Inventor	Eric L. LIEN	
	s many sheets as	nece	ssarv)	Group Art Unit	Not Yet Assigned	
	- · · · · · · · · · · · · · · · · · · ·		· · , /	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	AM101017	

	U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No.	U.S. Patent Document Number Kind Code (If known) (If Known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	<u>,</u> 1.	6,284,502		Maenz, et al	09-04-2001					
	2.	6,313,273	B1	Thomas, et al.	11-06-2001					
	3.	5,248,804		Nardelli, et al.	09-28-1993					
	4.	3,970,520		Feldman, et al.	07-20-1976					
	5.	4,100,024		Adler-Nissen	07-11-1978					
	6.	4,443,540		Chervan, et al.	04-17-1984					
	7.	6,126,973		Tsumura, et al.	10-03-2000					
	8.	6,221,423	B1	Cho, et al.	04-24-2001					

			FC	DREIGN P	ATENT DOCUMENTS			
Examiner	Cite		Foreign Patent Document	1	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials*	No.	Office	Number	Kind Code (If Known)	Applicant of Cited document	MM-DD-YYYY	Passages or Relevant Figures Appear	
	9.							

		OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
	10.	SAMUEL J. FOMON, "Isolated Soy Protein-Based Formulas", "Formulas Available in the United States", Nutrition of Normal Infants, 1993, page 428.	
	11.	HAROLD L. WILCKE, et al., "Soy Protein and Human Nutrition", Academic Press, Inc., 1979, pages 19-51.	
	12.	JOSEPH A. MAGA, "Phytate: Its Chemistry, Occurrence, Food Interations, Nutritional Significance, and Methods of Analysis", Journal of Agricultural and Food Chemistry, 19892, Vol. 30, pages 1-9.	
	13.	"Soy Protein-based Formulas: Recommendations for Use in Infant Feeding", Pediatrics, 1998 Vol. 101 No. 1, pages 148-153	
	14.	J. R. FORD, "Phytic Acid Removal from Soybeans by a Lipid Protein Concentrate Process", Journal of the American Oil Chemists' Society, 1978 Vol. 55 pages 371-374.	
	15.	BO LONNERDAL, et al., "Effect of reducing the phytate content and of partially hydrolyzing the protein in soy formula on zinc and copper absorption and status in infant rhesus monkeys and rat pups", Amer. J. Clin. Nutr., 1999, Vol. 69 (3), pages 490-496	
	16.	A. W. BURKS, et al., "Prospective oral food challenge study of two soybean protein isolates in patients with possible milk or soy protein enterocolitis", Pediatr. Allergy Immunol., Vol. 5, pages 40-45.	
	17.	A. W. BURKS, et al., "Identification and Comparison of Differences in Antigens In Two Commercially Available Soybean Protein Isolates", J. Food Science, 1988 Vol. 53 (5), pages 1456-1459	
	18.	L. JANAS, et al., "Tolerance of soy formulas with reduced phytate/phytoestrogens fed to healthy, term infants", Poster presented at the second international symposium on the role of soy in preventing and treating chronic disease, Brussells, Belgium, September, 1996	

Examiner Date Signature Considered		
	Signature	

DEC 1 5 2003 % INFORMATION STATEMENT E

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

use as many sheets as necessary)

of

1

1

Complete if Known					
Application Number 10/663,923					
Filing Date	September 16, 2003				
First Named Inventor	Eric L. LIEN				
Group Art Unit	Not Yet Assigned				
Examiner Name	Not Yet Assigned				
Attorney Docket Number	AM101017				

		,		U.S. PATENT DOCU	MENIS	
Examiner Initials*		U.S. Patent C	ocument		Date of Publication of	Pages, Columns, Lines,
	Cite No.	Number (If known)	Kind Code (If Known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
	1.	6,284,502		Maenz, et al	09-04-2001	
,	2.	6,313,273	B1	Thomas, et al.	11-06-2001	
	3.	5,248,804		Nardelli, et al.	09-28-1993	
	4.	3,970,520		Feldman, et al.	07-20-1976	
	5.	4,100,024		Adler-Nissen	07-11-1978	
	6.	4,443,540		Chervan, et al.	04-17-1984	
	7.	6,126,973		Tsumura, et al.	10-03-2000	,
	8.	6,221,423	B1	Cho, et al.	04-24-2001	

			F	OREIGN P	ATENT DOCUMENTS			
Examiner	Cite		Foreign Patent Document		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Initials*	No.	Office	Number	Kind Code (If Known)	Applicant of Cited document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T
	9.							

		OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	10.	SAMUEL J. FOMON, "Isolated Soy Protein-Based Formulas", "Formulas Available in the United States", Nutrition of Normal Infants, 1993, page 428.	
	11.	HAROLD L. WILCKE, et al., "Soy Protein and Human Nutrition", Academic Press, Inc., 1979, pages 19-51.	
	12.	JOSEPH A. MAGA, "Phytate: Its Chemistry, Occurrence, Food Interations, Nutritional Significance, and Methods of Analysis", Journal of Agricultural and Food Chemistry, 19892, Vol. 30, pages 1-9.	
	13.	"Soy Protein-based Formulas: Recommendations for Use in Infant Feeding", Pediatrics, 1998 Vol. 101 No. 1, pages 148-153	
	14.	J. R. FORD, "Phytic Acid Removal from Soybeans by a Lipid Protein Concentrate Process", Journal of the American Oil Chemists' Society, 1978 Vol. 55 pages 371-374.	
	15.	BO LONNERDAL, et al., "Effect of reducing the phytate content and of partially hydrolyzing the protein in soy formula on zinc and copper absorption and status in infant rhesus monkeys and rat pups", Amer. J. Clin. Nutr., 1999, Vol. 69 (3), pages 490-496	
	16.	A. W. BURKS, et al., "Prospective oral food challenge study of two soybean protein isolates in patients with possible milk or soy protein enterocolitis", Pediatr. Allergy Immunol., Vol. 5, pages 40-45.	
	17.	A. W. BURKS, et al., "Identification and Comparison of Differences in Antigens In Two Commercially Available Soybean Protein Isolates", J. Food Science, 1988 Vol. 53 (5), pages 1456-1459	
	18.	L. JANAS, et al., "Tolerance of soy formulas with reduced phytate/phytoestrogens fed to healthy, term infants", Poster presented at the second international symposium on the role of soy in preventing and treating chronic disease, Brussells, Belgium, September, 1996	

Examiner	Date
Signature	Considered